Targets › STEAP2
3 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Jan 2027.
Integral membrane protein that functions as a NADPH-dependent ferric-chelate reductase, using NADPH from one side of the membrane to reduce a Fe(3+) chelate that is bound on the other side of the membrane (By similarity). Mediates sequential transmembrane electron transfer from NADPH to FAD and onto heme, and finally to the Fe(3+) chelate (By similarity). (UniProt, Q8NFT2)
Open in Phaseline: the race on STEAP2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai AbelZeta | A-CAR032 dnTGFβRII-armoured STEAP2-targeted CAR T cell therapy | STEAP2 | Phase 1 | Prostate Cancer | Jan 2027 |
| AstraZeneca | AZD8359 STEAP2-targeting T cell engager (TCE) | STEAP2 | Phase 1 | Metastatic Prostate Cancer | Nov 2027 |
| AstraZeneca | AZD6621 T cell-engaging antibody targeting STEAP2, CD3, and CD8 | STEAP2, CD3, CD8 | Phase 1 | Prostate Cancer | Mar 2029 |
Prostate Cancer (2) Metastatic Prostate Cancer (1)
small molecule (2), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.